Payment overview · 2025
General Payments
$1,174.02
32 reported records · 15 companies
Healthcare provider profile · identity verified
Gerald Pierone, MD
Allopathic & Osteopathic Physicians|Internal Medicine · VERO BEACH, FL · NPI 1356387435
Verified facts
What the public records show
CMS Open Payments records show Gerald Pierone, MD received $1,174.02 in general payments during 2025 across 32 reported records.
REVANCE THERAPEUTICS, INC. accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cabenuva, Dovato.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Eliquis by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Descovy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vemlidy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $229.18 | 19.5% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $184.35 | 15.7% | 4 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $181.44 | 15.4% | 6 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $154.42 | 13.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $112.00 | 9.5% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $69.47 | 5.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $55.31 | 4.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.68 | 3.8% | 2 | 2025 |
| Solta Medical, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.90 | 2.8% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.97 | 2.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.06 | 1.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $18.34 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.08 | 1.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.33 | 1.3% | 1 | 2025 |
| QIAGEN, LLC | Unresolved — no canonical attribution shown | $13.49 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,174.02 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $184.35 | 4 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $154.42 | 1 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $147.91 | 4 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $112.00 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $69.47 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $55.31 | 2 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $47.78 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| CLEAR+BRILLIANT Normalized: clear brilliant |
Not specified | Solta Medical, a division of Bausch Health US, LLC | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $8.67 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 109 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
95 | 23 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 16 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
109 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 249 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 236 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 120 | 29 |
| Tivicay | Dolutegravir Sodium | 118 | 13 |
| Isentress | Raltegravir Potassium | 112 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 27 |
| Dovato | Dolutegravir Sodium/Lamivudine | 109 | 14 |
| Juluca | Dolutegravir/Rilpivirine | 103 | suppressed |
| Ozempic | Semaglutide | 102 | 16 |
| Omeprazole | Omeprazole | 100 | 18 |
| Eliquis | Apixaban | 95 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 25 |
| Losartan Potassium | Losartan Potassium | 90 | 20 |
| Alprazolam | Alprazolam | 88 | 17 |
| Simvastatin | Simvastatin | 82 | 16 |
| Trazodone Hcl | Trazodone Hcl | 82 | 11 |
| Azithromycin | Azithromycin | 78 | 42 |
| Etravirine | Etravirine | 78 | 11 |
| Gabapentin | Gabapentin | 76 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 75 | 18 |
| Descovy | Emtricitabine/Tenofov Alafenam | 73 | suppressed |
| Atenolol | Atenolol | 68 | 12 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 68 | suppressed |
| Ezetimibe | Ezetimibe | 66 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 13 |
| Temazepam | Temazepam | 61 | 13 |
| Acyclovir | Acyclovir | 60 | 12 |
| Allopurinol | Allopurinol | 58 | 12 |
| Valacyclovir | Valacyclovir Hcl | 58 | 18 |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 57 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 13 |
| Repatha Sureclick | Evolocumab | 44 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 44 | suppressed |
| Lisinopril | Lisinopril | 42 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 12 |
| Jardiance | Empagliflozin | 38 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 13 |
| Finasteride | Finasteride | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Efavirenz | Efavirenz | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Prednisone | Prednisone | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 17 |
| Testosterone | Testosterone | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Minoxidil | Minoxidil | 28 | 11 |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 28 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 28 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 17 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Metformin Hcl | Metformin Hcl | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Ramipril | Ramipril | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 13 |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 11 |
| Furosemide | Furosemide | 17 | suppressed |
| Lamivudine | Lamivudine | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Ritonavir | Ritonavir | 16 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Enbrel Sureclick | Etanercept | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Darunavir | Darunavir | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Atazanavir Sulfate | Atazanavir Sulfate | 13 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Tybost | Cobicistat | 13 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Prezista | Darunavir | 12 | suppressed |
| Serostim | Somatropin | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Emtricitabine | Emtricitabine | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Xiidra | Lifitegrast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,174.02 · 32 records | REVANCE THERAPEUTICS, INC. | AJOVY, Barostim Neo System, CABENUVA, CAMZYOS, CLEAR+BRILLIANT, DAXXIFY, DOVATO, LEQVIO, MITRACLIP, NEXLETOL, REPATHA, SAPIEN 3 Ultra RESILIA, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cabenuva play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error